Daily Management Review

Novartis Executive Named As Sanofi’s C.E.O


06/14/2019


Sanofi’s months-long search for new chief executive meets a successful end.



Sanofi is a French giant in the pharma industry which has announced Paul Hudson as its new C.E.O who is set to be Olivier Brandicourt’s successor post his retirement in September.
 
Hudson is a current “top executive” at Novartis, which is a Swiss rival of Sanofi, is going to take up his new responsibilities from September 1, 2019, confirmed Sanofi. A source from Sanofi had informed:
“Hudson has been chosen because of his reputation. He is known as a solid manager and has digital expertise relating to pharmaceuticals”.
 
Hudson if 51 years old and has been holding the chief executive’s chair of “Novartis Pharmaceuticals unit” from 2016, while his prior experiences include positions at “Schering Plough and AstraZeneca”. Moreover, as mentioned earlier, Hudson also holds a member’s position at the “Novartis executive committee”.
 
On the other hand, Marie-France Tschudin has been named to head the drug business at Novartis following Hudson’s departure. The search for a new C.E.O at Sanofi began some months ago.
 
Brandicourt, the current C.E.O of Sanofi joined the company in 2015 for helping it in reviving “the fortunes of France’s biggest drugmaker”. Since then, Brandicourt has been actively involved in “reshaping the business”. According to Reuters:
“Under his tenure, the company swapped its animal health unit with Boehringer Ingelheim in exchange for the German company’s consumer healthcare operations in a $20 billion (£15.8 billion) deal. It has also sold its European generics arm for 1.9 billion euros (£1.7 billion) to private equity firm Advent International.
“New launches such as eczema treatment Dupixent, cost-cutting measures and new priorities in research and development have also enabled Sanofi to return to profit in the second half of last year after a series of disappointing quarters”.
 
However, the teams of Brandicourt faced two major failures as “two strategic acquisitions” slipped through their hands, whereby Sanofi lost the chance of acquiring “California-based cancer specialist Medivation” which was bought over by Pfizer in the year of 2016 and the “Swiss biotech company Actelion” bought over by “Johnson & Johnson in 2017”.
 
 
References:
reuters.com







Science & Technology

Amazon will allow customers to pay with palms instead of cards

Complete Computer System For Self Driving Cars Launched By Qualcomm

In A Lifetime We Could Accumulate 20Kg Micro-Plastic In Our Body

Creator Of The First 'Gene-Edited' Babies Of The World Gets 3 Year Jail Term In China

China to deploy giant Beidou global navigation system in 2020

VW Zwickau factory is getting ready for electric cars production

Airbus: Passenger hybrid aircraft to take off before 2035

Ocado To Introduce ‘Mini Robotic Warehouse’ With Standard Productivity

AB InBev’s Piled Up Alcohol Is ‘Too Good to Waste’

Ericsson Mobility forecasts nearly fourfold increase in mobile traffic by 2025

World Politics

World & Politics

UK adds Greenpeace, PETA to extremist organizations list

Indonesia, UAE sign nearly $23B deal

US to respond to Iran’s attacks on US bases in Iraq

Irish Passport issues hit record in anticipation of Brexit

Reporters Without Borders calls to release Julian Assange

IMF allocates Ecuador $ 500 mln more to support reforms

French pension reform chief to resign

Poland refuses to join EU 2050 climate deal